Does Insurance Cover Wegovy or Ozempic? An Honest Guide

If you have searched "does Kaiser cover Ozempic" or "does TRICARE cover Wegovy," you already sense the frustrating truth: there is no single yes-or-no answer. Coverage for these drugs depends less on the molecule and more on why it is being prescribed, what your specific plan says, and whether you can clear a prior-authorization hurdle. This guide walks through how coverage actually works for semaglutide in mid-2026, why the diabetes brand is covered far more often than the weight-loss brand, and what your options are when you get a denial. Policies and formularies change constantly, so everything below is as of June 2026 — and none of it is medical, insurance, or financial advice. The only authoritative source for your situation is your own plan documents and your prescriber.

The one fact that explains almost everything: indication, not molecule

Ozempic and Wegovy are the same drug — both are semaglutide, made by Novo Nordisk — sold under two brand names because each went through a separate FDA approval for a different use. We unpack that fully in Ozempic vs Wegovy, but the coverage consequence is the single most important thing to understand here: insurers cover drugs by FDA-approved indication, not by active ingredient.

• •Ozempic is FDA-approved to improve blood sugar in adults with type 2 diabetes, to reduce major cardiovascular events in adults with type 2 diabetes and known heart disease, and to lower the risk of kidney decline in type 2 diabetes with chronic kidney disease¹. Weight loss is not on its label.
• •Wegovy is FDA-approved for chronic weight management in adults with obesity (or overweight plus a weight-related condition) and certain adolescents, for reducing cardiovascular risk in adults with established heart disease and obesity/overweight, and — more recently — for a form of fatty-liver disease (MASH) with moderate-to-advanced fibrosis².

Because diabetes is a near-universally covered medical condition and obesity has historically been treated by insurers as a lifestyle issue, Ozempic for diabetes is usually covered far more readily than Wegovy for weight loss. That asymmetry — same molecule, very different coverage odds — is the heart of this whole topic.

Commercial (employer/marketplace) plans: the most common scenario

Most working-age Americans get coverage through a commercial plan, and here the picture splits cleanly along the indication line.

Ozempic for type 2 diabetes is on most commercial formularies, typically as a preferred or non-preferred brand, often with a prior authorization confirming a diabetes diagnosis (an A1c value, a diagnosis code, or a trial of metformin first). The clinical case is strong — Ozempic's diabetes and cardiovascular benefits are backed by large outcome trials like SUSTAIN-6, which showed it reduced major cardiovascular events in people with type 2 diabetes³ — so payers generally accept it for its on-label use.

Wegovy for weight loss is where it gets hard. Many employer plans exclude anti-obesity medications entirely as a category, regardless of how strong the evidence is. When a plan does cover Wegovy, it almost always gates it behind:

• •a documented BMI threshold (commonly ≥30, or ≥27 with a weight-related condition, mirroring the label),
• •prior authorization with chart notes,
• •and sometimes step therapy — proof you tried diet/lifestyle programs or a cheaper medication first.

This is true even though Wegovy's weight-loss evidence is robust: the 68-week STEP 1 trial showed large average weight reduction versus placebo⁴, and the SELECT trial showed Wegovy-dose semaglutide cut cardiovascular events in people with obesity and heart disease but without diabetes⁵. Coverage policy and clinical evidence are simply two different things — strong trials do not force a plan to add a drug to its formulary.

A frequent and costly mistake: asking for Ozempic prescribed off-label for weight loss to get around a Wegovy exclusion. Insurers routinely deny this, because the claim shows a diabetes drug being used for a non-diabetes purpose with no diabetes diagnosis on file. The off-label route can also leave you paying cash — see Wegovy cost, GoodRx & the cheapest ways without insurance for what that actually runs.

"Does Kaiser cover Ozempic?" and other plan-specific questions

The honest answer to any "does [Kaiser / Aetna / BCBS / Cigna] cover [Ozempic / Wegovy]" question is: it depends on your specific plan within that insurer, your diagnosis, and the current formulary. Large insurers like Kaiser Permanente administer many different employer and individual plans, each with its own drug list and its own decision about whether anti-obesity medications are covered. Two people with Kaiser cards can have opposite answers.

The general pattern holds, though: Ozempic with a type 2 diabetes diagnosis is usually coverable (often after a PA), while Wegovy for weight loss may or may not be a covered benefit at all depending on whether that employer bought obesity-drug coverage. The only reliable way to know is to check your formulary (drug list) and call the member-services number on your card to ask, specifically, "Is Wegovy a covered benefit on my plan, and what are the prior-authorization criteria?"

Medicare: the statutory weight-loss exclusion (and the CV exception)

Medicare is the clearest-cut case, and it surprises people. By federal statute, Medicare Part D is prohibited from covering drugs used for weight loss. That is a law, not a plan choice — so a Part D plan generally cannot cover Wegovy when it is prescribed purely for weight management. Health-policy researchers have specifically flagged this Part D anti-obesity-medication exclusion as a coverage gap and called for reform⁶.

There are important nuances on top of that bright line:

• •Ozempic for type 2 diabetes is coverable under Part D, because that is a diabetes drug for a diabetes indication — the weight-loss exclusion does not apply.
• •The exclusion is tied to the use, not the molecule. After Wegovy gained an FDA indication to reduce cardiovascular risk in people with established heart disease and obesity, the door opened for Part D plans to cover Wegovy for that cardiovascular indication in eligible patients — because that use is not "weight loss" in the statutory sense. Coverage for the CV use is plan- and criteria-dependent and still evolving as of June 2026.
• •Medicaid coverage of anti-obesity drugs is optional and varies widely by state; some cover Wegovy with strict criteria, many do not.

The practical takeaway: if you are on Medicare and want semaglutide for weight loss alone, expect it not to be covered, and price out the cash routes in our Wegovy cost guide.

TRICARE and other government plans

TRICARE (military health coverage) and other federal programs each set their own rules and can change them. As a general matter, government plans have been more conservative than commercial plans on anti-obesity drugs, and — like Medicare — a diabetes indication for Ozempic is a far more straightforward path than a weight-loss indication for Wegovy. Because these policies are time-sensitive and beneficiary-specific, verify current TRICARE pharmacy formulary status directly rather than trusting a static figure online.

One thing that applies across all government plans (Medicare, Medicaid, TRICARE, VA): you are not eligible for the manufacturer's commercial savings card, which by law excludes people with government insurance. That changes the math on out-of-pocket cost considerably, as we detail in the cost and savings guide.

Prior authorization and step therapy, demystified

Even when a drug is on your formulary, "covered" rarely means "instant." The two gates you will most often meet:

• •Prior authorization (PA): your prescriber must submit documentation proving you meet the plan's criteria — a qualifying diagnosis, a BMI value, lab results, sometimes a record of prior attempts. The plan then approves or denies before it will pay.
• •Step therapy: the plan requires you to "fail" (try without adequate results) one or more cheaper or preferred options first — for weight management that might be lifestyle programs or an older medication; for diabetes it might be metformin before a GLP-1.

Neither is a flat no. They are paperwork hurdles, and a prescriber who documents thoroughly clears them far more often. Knowing the drug works the same regardless of brand can help that conversation — a pooled analysis of the SUSTAIN trials found semaglutide produced weight loss even in people who had no gastrointestinal side effects, underscoring that the benefit is pharmacologic, not incidental⁷. For what the drug actually does once you are on it, see our pillar, Semaglutide: How It Works, Results & Side Effects.

If you get denied: appeals

A denial is the beginning of a process, not the end of it. In broad strokes:

1. 1.Find out exactly why. The denial letter cites a reason — wrong indication, missing BMI, step-therapy not met, or a flat anti-obesity exclusion. The fix depends entirely on which it is.
2. 2.A formulary exclusion is different from a criteria miss. If your plan simply does not cover anti-obesity drugs at all, an appeal usually cannot manufacture a benefit that was never purchased — your realistic paths are cash-pay or a different plan at open enrollment. If instead you missed a criterion (a lab, a chart note), supplying it can flip the decision.
3. 3.Ask your prescriber for a letter of medical necessity and, if needed, a peer-to-peer review (your doctor talks directly to the plan's reviewer). Then escalate through the plan's internal appeal and, if available, an external/independent review.

Appeals are most winnable when the denial is procedural and your clinical case fits the label. They are least winnable against a true categorical exclusion. This is exactly where a prescriber's documentation earns its keep — and why the indication you are prescribed under (diabetes vs weight loss) so heavily shapes your odds.

The honest bottom line

Whether insurance covers Wegovy or Ozempic comes down to one question: what is it being prescribed for? Ozempic for type 2 diabetes is usually coverable across commercial and Medicare Part D plans, often after a prior authorization. Wegovy for weight loss is far less certain — many commercial plans exclude anti-obesity drugs outright, Medicare Part D is barred by statute from covering weight-loss use (with a narrowing exception for the cardiovascular indication), and government plans plus their savings-card lockout make cash cost the real consideration. Because coverage follows the FDA-approved use rather than the molecule, the most useful thing you can do is confirm your plan's formulary, understand the PA and step-therapy criteria, and lean on your prescriber's documentation. And remember semaglutide is ongoing therapy — the STEP 4 trial showed weight returns when it is stopped⁴⁸, so coverage is a long-run question, which we cover in What Happens If You Stop Semaglutide? and in side effects worth weighing. When you are ready to compare legitimate ways to start, our independent best semaglutide providers guide ranks options on price and oversight. Verify everything against your own plan as of June 2026 — this is a map, not advice.